Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 |
| clinicaltrials |
| NCT05718219 | Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors | terminated | Phase 1 | 49 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06342453 | CREATE: Art for Children With Cancer | recruiting | N/A | 72 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06818812 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | active not recruiting | Phase 1 | 30 | Incyte CorporationINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07141407 | Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person | recruiting | N/A | 80 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07193511 | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | recruiting | Phase 1 / Phase 2 | 355 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07681882 | First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 45 | Daiichi SankyoINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784777 | NK Cell Injection for Advanced Solid Tumors | not yet recruiting | Phase 1 | 9 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 25, 2026 | clinicaltrials |
| NCT07785609 | A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) | not yet recruiting | Phase 2 | 200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2026 | clinicaltrials |
| NCT02992210 | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05554380 | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 2 | Aug 24, 2026 | clinicaltrials |
| NCT05687136 | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | recruiting | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05901285 | Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Vaxiion TherapeuticsINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06417554 | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06803680 | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 90 | BeOne MedicinesINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT07659379 | Gotistobart Long Term Extension (LTE) Study | enrolling by invitation | Phase 3 | 20 | OncoC4, Inc.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07671768 | Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial | not yet recruiting | N/A | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07676903 | A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors | recruiting | Phase 1 | 170 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01772771 | Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program | recruiting | — | 12,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04447222 | Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors | active not recruiting | — | 1,242 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05765851 | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 108 | Daiichi SankyoINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | recruiting | Phase 1 / Phase 2 | 166 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07514819 | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma | recruiting | N/A | 100 | St. Jude Children's Research HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07595237 | A IIT Study of 177Lu-DOTA-SNA040 | recruiting | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07779798 | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.(TelOscope) | not yet recruiting | Phase 1 | 120 | Crossbow Therapeutics, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04572451 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | active not recruiting | Phase 1 | 50 | Yana NajjarOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04596384 | Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery | active not recruiting | N/A | 398 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06154291 | FIH XON7 in Advanced/Metastatic Solid Tumors(FIPO23) | recruiting | Phase 1 / Phase 2 | 255 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | suspended | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06304168 | Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study | recruiting | — | 6,150 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06741644 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 800 | CStone PharmaceuticalsINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT07775703 | HS-20117-2 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776899 | Clinical Applications of FAPI PET in Solid Tumors | recruiting | N/A | 200 | Ruijin HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00740805 | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT00918320 | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours(TOTEM2) | completed | Phase 2 | 129 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03454035 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | recruiting | Phase 1 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2026source: clinicaltrials